Tuesday, April 22, 2014 5:51:25 PM
In my own words and thoughts, more and more new money is going to come into this stock and right now I'm not sure many give much credence to the cell. Although it could be the biggest thing since sliced bread, and personally I feel we will get the patent approved, produce some quantity of panels, and then license a ton of them, I think most new investors are going to get on board in the near term future because of the growth the Sunworks division is providing. The Sunworks acquisition provides both revenue and profits that will enable the panel to come to fruition. As we continue to see investors get on board because of that, we should be grateful for any stock price increases it provides us (the company as well as shareholders). For the Sunworks division and the attention it garners via its 300% revenue increases YOY, will also bring momentum, swing and day traders. This will increase volume, volatility and hopefully the price along the way. I don't think the cell is going to garner that sort of attention until we have some real news about third party verification of efficiency, and/or concrete production partners.
I look at the "mathematical possibility" (which I realize is far from the probable reality) that there is a chance the panel could fall through. There could be a hangup with the patent, there could be a problem with the production. (again -small but not zero) - If this injustice occurs, we won't all lose our money. We will all be disappointed, but the SUNworks team will continue to thrive despite having to purchase panels from another producer. I imagine if we are achieving 300% YOY organic growth with these purchased panels, if and when we do produce our own, or have a deal in place for super low priced panels due to licensing, we'll be popping champagne together in Melbourne. But I can't discount people as being either uniformed, or incorrect because of their opinions (that are their own to have), that a delay in panel production, patent approval or high cost of R&D could be seen as a downside risk to an investor.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM